Colinz

Kind Attention: Mr. S. Subramanian, DCS-CRD

30-0t-2016
To,

The Stock Exchange, Mumbai

P. J. Towers, Dalal Street
Mumbai - 4OO O23.
Dear Sir,

Sub : Quarterly Results ( Subjected to Limited Review by the Auditors

Ref : Code of the Company - 53L210 I COLINZ LABOR
As per clause

4l

of the Listing Agreement, we are sending herewith the financial

results (Subjected to Limited Review by the Auditors) for the quarter ended
31st December, 2OI5. Which has been taken on record in the Board meeting held
on 30-0L-2OL6.

Thanking you,
Yours faithfully,
For COLINZ LABORATORIES LTD.,

c&rfur>d ory

sof

Colinz Laboratories Limited

rrrNr

\T^- T rarrnMl{1qR6pI

r-O41 17R

rlte

Colinz
COLINZ LABORATORIES LIMITED.
A-101, Pratik lnd. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai

400 078.

(CIN NO : L24200MH1986PLc041128)

UN-AUDITED RESULTS FORTHE THIRD QUARTER ENDED

31St DECEMBER, 2015

(Rupees in " 000"1

S. No.

Particulars

31-Dec-15
PART
1

6
o

10

11

12

31-Dec-15

31

Year

-Dec-14

3't-Mar-15

82,112
3,255
78,857
78,857

Gross Sales
Less Excise Duty

19,352

20,291

18,993

64,443

525

647

462

1,858

Net Sales/lncome From Operation

(b) Other Operating lncome
Total lncome from Operation

18,827

19,644

18,531

62,585

64,244
2,447
61,797

'|.8,827

19,644

18,531

62,585

61,797

11,127
8,555
7,599

12,216

16,372

27,076

Expenditure
(a) Cost Of Material Consumed
(b) Purchase of Goods Traded

(0

3l-Dec-'14

(a)lncome from Operation

3,601

3,346

3,081

2,363
1,598

4,534

4,914

0e)

7,175

7,536

(1,426)
7,903

703
3,049
18,489
338
221

702

655

in stock in trade

Other Expenditure

Total Expenditure

30-Sep-15

Audited

-I

(c) (lncrease)/Decrease
(d) Staff Cost
(e) Depreciation

Un -audited
Nine Month Ended

n -nrrdifed
Quarter ended

Profit /(Loss) from Operation Before Other lncome ( 1-2)

Other lncome/(Loss)

3,300

2,930

9,831

18,463
(3,718)
22,O15
1,965
9,543

19,309
335

18,057

61,219

60,484

77,354

474

302

274

1,366
685

1,313
786

1,503
1,103

(1

22,001
2,107

(e,7e5)

27,663
2,975
13,063

Profit /Loss before lnterest & Exceptional items (3+4)

lnterest

559
271

bJ/

748

2,051

2,099

2,606

260

391

869

824

1,151

Profit /Loss after lnterest but before exceptional items (5-6)

Exceptional items
Profit /Loss before Tax (7-8)
Tax Expenses ( Provision for Taxation ) Current tax
Deffered tax

288

377

357

1,1 82

1,275

1,455

288
(40)
(50)

377
(75)
(e5)

357
(60)
(65)

1,182
(1s5)
(1e5)

1,275
(1e5)
(1e5)

1,455
(267)
(223)

198
354,41

207

232

792

354,39

354,35

354,41

885
354,35

965
354,39

Net ProfiUloss afterTax (9-10)

Paid up Equlty Share Capital ( Face Value 10/- Per Share

[Net of allotment money in arrears]

13

Reserves Excluding Revaluation Reserves

14

Earning per share (EPS) before extraordinary item( not Annualised)

i)
ii)

7,470
o.21

Basic & Diluted

Diluted

PART.II PARTICULARS OF SHAREHOLDING

Public Shareholding
I

i)
ii)
2

Number of Shares

2,894,901

Percentage of shareholding

2,894,901
63.33%

2,894,901
63.33%

2,894,901

2,894,901

63.33%

63.33%

63.33%

2,894,901
63.33%

1,676,099

1,676,099

1,676,099

1,676,099

1,676,099

1,676,099

36.67%

36.670/o

36.67%

36.67o/o

36.67%

36.67o/o

100o/o

100%

100%

100o/o

100%

Promoters and promoter group Shareholding

a) Pledged/Encumbered

l) Number of shares
ll)Percentage of shares (as a % of the total shareholding of promoter
and promoter group)
lll)Percentage of shares (as a% of the total share capital of the company)
b) Non-encumbered
i) Number of Shares

ii)Percentage of shares (as

aolo of

the total shareholding of promotor and

promoter group)
iii)Percentage of shares (as a % of the total share capital of the company)

Colinz Laboratories Limited

rnolhr

a6r1a^^

101o/o

h,

Colinz
B

INVESTORS COMPLAINTS

3 MONTHS ENDED 3I-12.20,15

i)Pending at Begining of the Quarter

Nit

ii)Received During the Quarter

Nit

iii)Disposed of During the Quarter

Nit

iv)Remaining at the end of the Quarter

Nit

NOTE S:'l .

The above financial results have been reviewed by the Audit Committee and approved by

the Board of Directors

at their respective meetings held

on 30-01-2016.
2. The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is
not applicable
3) Previous period figures have been regrouped wherever required.

For and on behalf of the Board

GoLTNZAABORATORTES LTD.
crN No L2t200Mr7le86PLC04l128

\Lkz

MUMBAI.

30.01.2016

\Dr. lJ. S. MANI

(Managing Director.)
( DIN NO : 00825886)

llalint

I aharalrtriac I itnilad